MELARIS^®

Testing for Hereditary Melanoma

What is MELARIS^®?
MELARIS^® assesses an individual's risk of developing
melanoma, based on the detection of mutations in the p16 gene.

What is the test?
MELARIS^® is a genetic test that requires only a small blood
sample to determine if a patient has a p16 gene mutation,
indicating a predisposition for melanoma. This is the most
accurate clinical test available to detect p16 gene mutations.

Why chose the MELARIS^® test?
MELARIS^® genetic testing enables the clinician to:

• Take a proactive management approach with clearly identified at-risk patients
• Avoid unnecessary interventions in family members who have not inherited a known familial mutation
• Target increased surveillance and other interventions to individuals with a p16 mutation – maximising patient care while increasing clinical efficiency
• Counsel patients and family members on the underlying cause of cancer, in the case of a positive result. Significantly improve patient outcomes.

Myriad and MELARIS are either trademarks or registered trademarks of Myriad Genetics, Inc in the United States and other jurisdictions.